From KBL to Cure

For most Ilonggos, Kadyos (pigeon pea) is synonymous with comfort food—the earthy anchor of the beloved KBL (Kadyos, Baboy, Langka). But for the scientists at the University of San Agustin (USA), this humble legume isn’t just lunch; it is a potential weapon against one of the world’s deadliest threats.

The university’s recent licensing agreement with MARIDAN Industries Inc. to commercialize a Kadyos-based antibiotic is a massive win, but not just for the academe. It is a roadmap for how the Philippines can transition from a consumer economy to a producer of high-value innovation.

First, let’s look at the stakes. The World Health Organization identifies antimicrobial resistance (AMR) as a top global health threat, predicting it could kill 10 million people annually by 2050. We are running out of drugs that work. That Dr. Doralyn Dalisay and her team found active compounds in Kadyos capable of fighting multidrug-resistant Staphylococcus aureus is a triumph of ethnobotany. It validates what our ancestors intuitively knew: the cure is often growing in our own backyard.

However, the science is only half the story. The signing of this Technology Licensing Agreement marks a critical shift from the “Ivory Tower” to the market shelf.

For decades, the metric for success in Philippine Higher Education Institutions (HEIs) has been publication. Professors write papers, present them at conferences, and then file them away to gather dust. This model does not create wealth. The USA-MARIDAN deal disrupts this cycle. By securing a patent that protects this technology until 2042 and partnering with a local pharmaceutical player, USA is proving that research must pay dividends—literally.

This is the beginning of a local knowledge economy. We shouldn’t just be exporting nurses and engineers; we should be exporting patents and products.

Yet, we cannot romanticize the struggle it took to get here. Dr. Dalisay noted that the research, which began in 2016, persisted “despite funding constraints.” This is a polite way of highlighting a chronic national failure. The Philippines generally spends less than 0.5% of its GDP on Research and Development (R&D), well below the UNESCO recommendation of 1%.

While the Department of Science and Technology (DOST) stepped in during the pandemic, our scientists should not have to rely on “diskarte” (ingenuity) and martyrdom to survive. Innovation is expensive. Bringing a drug from discovery to pharmacy shelves costs millions. If the government wants a First World economy, it cannot continue allocating Third World budgets to R&D. We need consistent investment, not just sporadic grants when a crisis hits.

Finally, the brilliance of this specific patent lies in its foresight regarding food security. In a country where inflation can make a simple vegetable stew expensive, there is a valid fear that industrializing a crop for pharma could drive up food prices. However, the USA team’s method extracts the antibiotic metabolites without competing with the food supply. It is responsible biotechnology: we can have our KBL and our medicine, too.

This patent is a vote of confidence in Filipino ingenuity, but it is also a challenge. To the government: fund the labs. To other universities: stop writing for shelves and start inventing for the market. And to the Ilonggos: look at your bowl of KBL with a little more respect. It might just save your life one day.